PODD

308.68

0.31% -0.95

Handel nachbörslich: 306.01 -2.67 -0.86%

Insulet Corporation (PODD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PODD? Forum Prognose

Schlusskurs vom Vortag:

$309.63

Offen:

$312.04

24-Stunden-Volumen:

804.28K

Relative Volume:

1.00

Marktkapitalisierung:

$21.72B

Einnahmen:

$2.20B

Nettoeinkommen (Verlust:

$402.20M

KGV:

55.52

EPS:

5.56

Netto-Cashflow:

$280.80M

1W Leistung:

+11.32%

1M Leistung:

+6.69%

6M Leistung:

+9.41%

1J Leistung:

+58.63%

1-Tages-Spanne:

$306.91

$314.35

1-Wochen-Bereich:

$286.68

$322.80

52-Wochen-Spanne:

$180.31

$329.33

Insulet Corporation Stock (PODD) Company Profile

Firmenname

Insulet Corporation

Sektor

Healthcare (1161)

Branche

Medical Devices (149)

Telefon

978-600-7000

Adresse

100 NAGOG PARK, ACTON, MA

Mitarbeiter

3,900

Twitter

@insulet_uk

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PODD's Discussions on Twitter

Vergleichen Sie PODD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PODD Insulet Corporation	308.68	21.46B	2.20B	402.20M	280.80M	5.56
ABT Abbott Laboratories	129.40	228.63B	43.11B	13.98B	6.78B	7.98
BSX Boston Scientific Corp	102.50	152.25B	18.49B	2.51B	3.23B	1.68
SYK Stryker Corp	378.95	144.00B	23.82B	2.92B	4.02B	7.55
MDT Medtronic Plc	92.91	118.82B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	77.68	45.89B	5.69B	4.14B	577.90M	6.96

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-16	Eingeleitet	Truist	Buy
2025-05-30	Eingeleitet	Goldman	Buy
2025-05-13	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-04-29	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-03-06	Eingeleitet	RBC Capital Mkts	Outperform
2024-11-06	Eingeleitet	Bernstein	Outperform
2024-05-30	Eingeleitet	Redburn Atlantic	Buy
2024-05-07	Hochstufung	Wolfe Research	Peer Perform → Outperform
2023-12-21	Hochstufung	Robert W. Baird	Neutral → Outperform
2023-12-04	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-10-02	Hochstufung	Jefferies	Hold → Buy
2023-08-21	Hochstufung	Citigroup	Neutral → Buy
2023-08-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2023-05-30	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-01-26	Eingeleitet	Wolfe Research	Peer Perform
2022-11-04	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-18	Eingeleitet	Barclays	Equal Weight
2022-10-12	Eingeleitet	Jefferies	Hold
2022-07-11	Herabstufung	Citigroup	Buy → Neutral
2022-03-02	Fortgesetzt	BofA Securities	Buy
2022-02-03	Hochstufung	BTIG Research	Neutral → Buy
2022-02-02	Hochstufung	UBS	Neutral → Buy
2022-01-31	Hochstufung	Oppenheimer	Perform → Outperform
2021-07-21	Fortgesetzt	Cowen	Outperform
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-01	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-03-19	Hochstufung	Canaccord Genuity	Hold → Buy
2021-01-29	Herabstufung	Piper Sandler	Overweight → Neutral
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-07-28	Eingeleitet	Wells Fargo	Overweight
2020-04-24	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-04-03	Eingeleitet	BofA/Merrill	Neutral
2020-03-31	Herabstufung	Berenberg	Buy → Hold
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-10	Eingeleitet	CFRA	Sell
2019-10-23	Eingeleitet	Stifel	Hold
2019-10-18	Herabstufung	Canaccord Genuity	Buy → Hold
2019-10-14	Herabstufung	BTIG Research	Buy → Neutral
2019-10-04	Herabstufung	UBS	Buy → Neutral
2019-10-03	Herabstufung	Guggenheim	Buy → Neutral
2019-08-06	Hochstufung	JP Morgan	Neutral → Overweight
2019-06-10	Herabstufung	Northland Capital	Outperform → Market Perform
2019-05-06	Hochstufung	BTIG Research	Neutral → Buy
2018-04-20	Eingeleitet	Berenberg	Buy
2018-02-22	Bestätigt	Barclays	Overweight
2018-01-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2017-11-03	Hochstufung	Canaccord Genuity	Hold → Buy
2017-09-15	Eingeleitet	Barclays	Overweight

Alle ansehen

Insulet Corporation Aktie (PODD) Neueste Nachrichten

06:10 AM

PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - Yahoo Finance

06:10 AM

02:00 AM

Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Patterns & Weekly Chart Analysis and Guides - 선데이타임즈

02:00 AM

Aug 12, 2025

Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - Yahoo Finance

Aug 12, 2025

Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st

Aug 11, 2025

Aug 10, 2025

Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru

Aug 10, 2025

Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN

Aug 10, 2025

Aug 09, 2025

Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest

Aug 09, 2025

Aug 08, 2025

Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛

Aug 08, 2025

RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest

Aug 08, 2025

Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest

Aug 08, 2025

Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st

Aug 08, 2025

Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener

Aug 08, 2025

Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada

Aug 08, 2025

Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria

Aug 08, 2025

RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener

Aug 08, 2025

Insulet price target raised to $350 from $330 at RBC Capital - TipRanks

Aug 08, 2025